1. Cell Cycle/DNA Damage
  2. HDAC

Panobinostat (Synonyms: LBH589; NVP-LBH589)

Cat. No.: HY-10224 Purity: 98.42%
Handling Instructions

Panobinostat is a non-selective histone deacetylase (HDAC) inhibitor.

For research use only. We do not sell to patients.

Panobinostat Chemical Structure

Panobinostat Chemical Structure

CAS No. : 404950-80-7

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO USD 73 In-stock
Estimated Time of Arrival: December 31
10 mg USD 66 In-stock
Estimated Time of Arrival: December 31
50 mg USD 132 In-stock
Estimated Time of Arrival: December 31
100 mg USD 180 In-stock
Estimated Time of Arrival: December 31
200 mg USD 228 In-stock
Estimated Time of Arrival: December 31
500 mg USD 468 In-stock
Estimated Time of Arrival: December 31
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

Customer Review

    Panobinostat purchased from MCE. Usage Cited in: China Biotechnology. 2016, 36(6): 9-17.

    The HDAC expression of PC3 cell with different concentration of Panobinostat. (a) HDACs mRNA expression is analyzed by real time PCR (b) HDACs protein expression is analyzed by Western blot.
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References


    Panobinostat is a non-selective histone deacetylase (HDAC) inhibitor.

    In Vitro

    Panobinosta (LBH589) induces apoptosis of both MOLT-4 and Reh cells in a time- and dose-dependent manner. Panobinosta treatment results in histone (H3K9 and H4K8) hyperacetylation and regulation of cell-cycle control genes in Reh cells[1]. Panobinostat exhibites potent antiproliferative activity in human NSCLC cell lines with the IC50 ranging from 5 to 100 nM[2].

    In Vivo

    Panobinosta (10, 20 mg/kg, i.p.) significantly slows tumor growth derived from Meso and NSCLC cells in vivo models. Panobinosta markedly increases acetylation of histone H3 and H4 of H69 human SCLC cells harvest from SCID mice[2]. Panobinostat (5, 10 and 20 mg/kg i.p.) demonstrates a clear benefit of decreased tumor burden, significantly improves TTE and reduces bone density loss in a disseminated multiple myeloma mouse model[3].

    Clinical Trial
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 57 mg/mL (163.12 mM)

    *"≥" means soluble, but saturation unknown.

    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.8618 mL 14.3090 mL 28.6180 mL
    5 mM 0.5724 mL 2.8618 mL 5.7236 mL
    10 mM 0.2862 mL 1.4309 mL 2.8618 mL
    *Please refer to the solubility information to select the appropriate solvent.
    Cell Assay

    Cells are washed with ice-cold PBS containing 0.1 mM sodium orthovanadate, and total proteins are isolated using RIPA lysis buffer, which includes protease inhibitors (leupeptin, antipain, and aprotinin), 0.5 mM PMSF, and 0.2 mM sodium orthovanadate. Protein amounts are quantified using the Bio-Rad protein assay. Equal amounts of proteins are loaded onto an sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel, transferred onto nitrocellulose membrane, and probed with the antibody of interest: mouse monoclonal c-Myc and mouse monoclonal p21 antibodies; rabbit polyclonal phospho-Histone H2A.X, rabbit polyclonal acetyl-Histone H3 (Lys9), and rabbit polyclonal acetyl-Histone H4 (Lys8) antibodies; mouse monoclonal p27/KIP1 antibody; mouse monoclonal anti-β-actin; and mouse monoclonal anti-GADD45G. Membranes are then washed, reprobed with appropriate horseradish peroxidase-conjugated secondary antibodies, and developed with SuperSignal chemiluminescent substrate.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration

    AE17 and TC-1 cancer cells (1×106 cells) are injected into the flanks of adult female C57Bl/6 mice and severe combined immunodeficiency (SCID) mice. M30 (10×106 cells), A549 (5×106 cells), H69 (2.5×106 cells), BK-T (6.5×106), H526 (10×106), and RG1 (10×106) cells are also injected, but in the presence of matrigel, into the flanks of SCID mice. When tumors reach 100 to 500 mm3, panobinostat is administered via i.p. injections (10-20 mg/kg) on a daily schedule (5-days-on, 2-days-off regimen) for the entire duration of the experiment. Control micereceive i.p. injections with dextrose 5% in water. Every tumor is measured with a caliper at least twice weekly. For evaluation of the effects of combination therapy on SCLC-derived tumors, SCID mice with H69 tumors are administered panobinostat. Three days after the initiation of panobinostat, and again 1 wk later, etoposide (40 mg/kg) is administered i.p.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Molecular Weight




    CAS No.




    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month

    Room temperature in continental US; may vary elsewhere

    Purity: 98.42%

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name



    Applicant name *


    Email address *

    Phone number *


    Organization name *

    Country or Region *


    Requested quantity *


    Bulk Inquiry

    Inquiry Information

    Product Name:
    Cat. No.:


    Cat. No.: HY-10224